1. Systematic review:
Corinna Dressler, Jo Lambert, Lynda Grine, Paul Galdas, Carle Paul, Miriam Zidane, Alexander Nast
Journal der Deutschen Dermatologischen Gesellschaft (accepted).
Psoriasis is a chronic inflammatory skin condition. Patient education may be one option to improve adherence and coping. The aim of this systematic review is to identify studies evaluating educational interventions for psoriasis patients. The review was conducted following the methods recommended by Cochrane. We searched seven databases, one trial register and three grey literature repositories. Data screening and extraction was done by two t reviewers independently. The risk of bias 2.0, ROBINS-I, NIH-tool were used. Additionally, the APEASE criteria were applied. We evaluat ed 16 studies. Two RCTs evaluated patient-practitioner or patient-nurse one-to-one interventions, one RCT assessed a web-based intervention, three RCTs reported group interventions taking place frequently; one RCT reported one-off group sessions. The remaining RCT compared the health care professionals involved. The risk of bias rating ranged from ‘some concerns’ to ‘high’. Three RCTs found an effect. We included 4 CCTs - one had an effect. One of 4 included before-after-studies warrants further investigation. Despite similarities in delivery mode across the interventions, patients eligible and settings in which interventions were delivered differed. Interventions that included an individual (one-to-one) session appear successful. Two interventions seem suitable for adaptation using APEASE: the topical treatment program (1, 2) and motivational interviewing after climate therapy(3, 4).
The review is being kept updated in form of a living systematic review. We will be searching for new studies every six months starting January 2019.
Table 1: Living Review History
Mota (5) evaluated the effect of several oral education sessions (30 minutes) on awareness of cardiovascular comorbidities amongst psoriasis patients. They report an improvement in knowledge of these comorbidities after the session and after six months. The impact on psoriasis or quality of life was not assessed. Our critical appraisal of the study lead to poor due to suboptimal reporting.
Najafi-Ghezeljeh(6) recruited patients hospitalized with psoriasis to participate in a self-management education intervention comprised of three group session and three telephone calls during which the disease, treatment options, lifestyle and behaviour were discussed. After 3 months, no difference between the intervention and the routine care groups based on final DLQI (mean difference -1.23 [-3.70; 1.24], but a difference was seen based on the mean change in PASI (- 4.21 [-7.81; -0.61]). The risk of bias evaluations lead to moderate for the outcome PASI and serious for the outcome DLQI (ROBINS-I for non-randomized studies). Authors gave no feedback.
Table 2: APEASE(7) evaluation of additional studies
1. Reich K, Mrowietz U, Karakasili E, Zschocke I. Development of an adherence-enhancing intervention in topical treatment termed the topical treatment optimization program (TTOP). Arch Dermatol Res. 2014;306(7):667-76.
2. Reich K, Zschocke I, Bachelez H, de Jong EMGJ, Gisondi P, Puig L, et al. A Topical Treatment Optimisation Programme (TTOP) improves clinical outcome to calcipotriol/betamethasone gel in psoriasis: Results of the 64-week, multinational, randomized, phase IV study in 1790 patients (PSO-TOP). Br J Dermatol. 2017;177(1):197-205.
3. Larsen MH, Krogstad AL, Aas E, Moum T, Wahl AK. A telephone-based motivational interviewing intervention has positive effects on psoriasis severity and self-management: a randomized controlled trial. Br J Dermatol. 2014;171(6):1458-69.
4. Larsen MH, Wahl AK, Krogstad AL, Aas E. Cost-utility Analysis of Supported Self-management with Motivational Interviewing for Patients with Psoriasis. Acta Derm Venereol. 2017;96(5):664-8.
5. Mota F, Selores M, Torres T. Importance of educational sessions on cardiometabolic comorbidities. Awareness among psoriasis patients. Actas Dermo-Sifiliograficas. 2016;107(6):539-41.
6. NAJAFI GHEZELJEH T, SOLTANDEHGHAN K, HOSEINI F. The effect of self-management education on the quality of life and severity of the disease in patients with psoriasis: A clinical trial. Nursing Practice Today. 2018;5(1):243-55.
7. Michie S, Atkins L, West R. The behaviour change wheel : a guide to designing Interventions2014.
8. Bundy C, Kaur-Pinder B, Bucci S, Tarrier N, Griffiths CEM. Managing psychological morbidity in patients with psoriasis using a novel online treatment programme: the e-TIPs study. Br J Dermatol. 2011;165:54.
9. Bundy C, Pinder B, Bucci S, Reeves D, Griffiths CEM, Tarrier N. A novel, web-based, psychological intervention for people with psoriasis: the electronic Targeted Intervention for Psoriasis (eTIPs) study. Br J Dermatol. 2013;169(2):329-36.
10. Bostoen J, Bracke S, De Keyser S, Lambert J. An educational programme for patients with psoriasis and atopic dermatitis: a prospective randomized controlled trial. Br J Dermatol. 2012;167(5):1025-31.
11. Bostoen J, Geusens B, Lambert J, Bracke S, Dekeyser S. An educational program for patients with psoriasis and atopic dermatitis: A prospective randomized, controlled trial. J Am Acad Dermatol. 2012;1):AB84.
12. Rothman AI, Byrne N, Schachter RK, Rosenberg L, Mitchell D. An educational program for psoriatics: an evaluation. Eval Health Prof. 1980;3(2):191-203.
13. Thongkaow S, Kongsin S, Jiamton S, Chunhasewee C, Pratchayapruit W. The Effectiveness of Participation in Self-Help Group on Self-Care Ability and Disease Severity Among Patients with Psoriasis [Master Thesis]. Bangkok: Mahidol University; 2016.
14. Ersser SJ, Cowdell FC, Nicholls PG, Latter SM, Healy E. A pilot randomized controlled trial to examine the feasibility and efficacy of an educational nursing intervention to improve self-management practices in patients with mild-moderate psoriasis. J Eur Acad Dermatol Venereol. 2012;26(6):738-45.
15. Lora V, Gisondi P, Calza A, Zanoni M, Girolomoni G. Efficacy of a single educative intervention in patients with chronic plaque psoriasis. Dermatology. 2009;219(4):316-21.
16. Bremer Schulte M, Cormane RH, van Dijk E, Wuite J. Group therapy of psoriasis. Duo formula group treatment (DFGT) as an example. J Am Acad Dermatol. 1985;12(1 Pt 1):61-6.
17. Fortune DG, Richards HL, Griffiths CE, Main CJ. Targeting cognitive-behaviour therapy to patients’ implicit model of psoriasis: Results from a patient preference controlled trial. Br J Clin Psychol. 2004;43(1):65-82.
18. Fortune DG, Richards HL, Kirby B, Bowcock S, Main CJ, Griffiths CEM. A cognitive-behavioural symptom management programme as an adjunct in psoriasis therapy. Br J Dermatol. 2002;146(3):458-65.
19. Pagliarello C, Calza A, Armani E, Di Pietro C, Tabolli S. Effectiveness of an empowerment-based intervention for psoriasis among patients attending a medical spa. Eur J Dermatol. 2011;21(1):62-6.
20. Renzi C, Di Pietro C, Gisondi P, Chinni LM, Fazio M, Ianni A, et al. Insufficient knowledge among psoriasis patients can represent a barrier to participation in decision-making. Acta Derm Venereol. 2006;86(6):528-34.
21. Burnett CJ, Gordon K, Kundu RV. Psoriasis and cardiometabolic disease: An educational and teaching intervention on cardiometabolic risks. J Am Acad Dermatol. 2015;1):AB101.
22. Burnett CJ, West DP, Rademaker AW, Kundu RV. Psoriasis and Cardiometabolic Disease: A Brief, Focused, Educational Intervention on Cardiometabolic Risks. Journal Of Drugs In Dermatology. 2016;15(10):1176-80.
23. de Korte J, Van Onselen J, Kownacki S, Sprangers MAG, Bos JD. Quality of care in patients with psoriasis: an initial clinical study of an international disease management programme. J Eur Acad Dermatol Venereol. 2005;19(1):35-41.
24. Tucker R, Stewart D. Assessing the impact of community pharmacist led educational advice on knowledge, disease severity and quality of life in patients with mild to moderate psoriasis. Int J Pharm Pract. 2016;24:22.
25. Wahl AK, Moum T, Robinson HS, Langeland E, Larsen MH, Krogstad AL. Psoriasis Patients’ Knowledge about the Disease and Treatments. Dermatol Res Pract. 2013;2013:921737-.
2. Expert survey & Interviews:
[Work in progress]
- 2020/03/13 Focus on...In Memoriam-Prof Dr Nelida Aurora Raimondo (1952–2020)News:In Memoriam-Prof Dr Nelida Aurora Raimondo (1952–2020)
- 2019/10/29 Focus on...World Psoriasis Day 2019
- 2019/08/12 Focus on...Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis
- 2019/06/03 Focus on...News from our SPIN Columbian members
- 2019/05/21 Focus on...SPIN2019 is now available on your screen!
Prof Nelida Aurora Raimondo
- 2020/03/13 Focus on...In Memoriam-Prof Dr Nelida Aurora Raimondo (1952–2020)News:In Memoriam-Prof Dr Nelida Aurora Raimondo (1952–2020)
News from the web office
- 2017/06/05PIN becomes SPIN - Skin Inflammation & Psoriasis International Network
- 2016/10/29PSO 2016 Congress - Webcasts Available!
- 2016/05/26PIN Survey on Phototherapy
- 2016/02/20PIN Study on Therapeutic Patient Education
- 2016/02/19World Directory of Psoriasis Medical Resources - February 2016 Update
- 2019/04/18 Focus on...SPIN Congress 2019 in Paris coming soon
- 2018/07/16SPIN Symposium at the Spring continental meeting - Tehran, 25-27 April 2018
- 2018/02/222nd National Meeting of the Egyptian Society for Psoriasis
- 2018/02/211st Psoriasis Symposium - Sarajevo 2017
- 2017/06/2815th São Paulo Meeting of Psoriasis and Vitiligo
News from medical groups
- 2018/04/183rd Turkish National Psoriasis Symposium
- 2017/06/21Brazilian Center for Psoriasis Studies joins SPIN!
- 2017/06/21Costa Rica Psoriasis Group - Meet them!
- 2017/02/02Works of the 1st Senegalese Psoriasis Day published!
- 2016/07/29Swiss S1 Guidelines for Systemic treatment of psoriasis vulgaris
News from patients associations
- 2017/02/08France Psoriasis - 2016 World Psoriasis Day
- 2016/05/26Senegal Patients Association joins PIN!
- 2015/08/04Epidermia Greece: a new partner association of PIN
- 2015/08/01Canadian Association of Psoriasis Patients joins PIN!
- 2015/04/09AEPSO Argentina launches digital map to find people with psoriasis in the country
Recent publications on Psoriasis and Atopic Dermatitis
Discovery of the potent non-steroidal glucocorticoid receptor modulator BAY 1003803 as clinical candidate.
Bioorg. Med. Chem. Lett.. 2020 Aug 15, 30, (16):127298.
We report on the discovery of the new clinical candidate BAY 1003803 as glucocorticoid receptor agonist for the topical treatment of psoriasis or severe atopic dermatitis. In the course of optimizing the amino alcohol series as a highly potent new non-steroidal lead structure, considerations were made as to how physicochemical properties and safety concerns relate to structural motifs. BAY 1003803 demonstrates strong anti-inflammatory activity in vitro paired with a pharmacokinetic profile (...)see on pubmed
Immobilization of papain enzyme on a hybrid support containing zinc oxide nanoparticles and chitosan for clinical applications.
Carbohydr Polym. 2020 Sep 01, 243:116498.
A new hybrid bionanomaterial composed of zinc oxide nanoparticles (ZnO NPs) and chitosan was constructed after enzymatic immobilization of papain for biomedical applications. In this work, we report the preparation and characterization steps of this bionanomaterial and its biocompatibility in vitro. The properties of the immobilized papain system were investigated by transmission electron microscopy, zeta potential, DLS, UV-vis absorption spectroscopy, FTIR spectroscopy, and X-ray (...)see on pubmed
Tackling the various classes of nano-therapeutics employed in topical therapy of psoriasis.
Drug Deliv. 2020 Dec , 27, (1):662-680.
Psoriasis is a dermatological chronic skin condition with underlying autoimmune etiology. It deeply affects patients' quality of life. Therefore, it was an interesting target for researchers throughout the past years. Conventionally, the treatment options include anti-inflammatory agents, immune suppressants, biologic treatment, and phototherapy. Nanotechnology offers promising characteristics that allow for tailoring a drug carrier to achieve dermal targeting, improved efficacy and (...)see on pubmed
Diagnostic Models for Atopic Dermatitis Based on Serum Microbial Extracellular Vesicle Metagenomic Analysis: A Pilot Study.
Allergy Asthma Immunol Res. 2020 Sep , 12, (5):792-805.
Associations between a wide variety of diseases and the microbiome have been extensively verified. Recently, there has been a rising interest in the role the microbiome plays in atopic dermatitis (AD). Furthermore, metagenomic analysis of microbe-derived extracellular vesicles (EVs) has revealed the importance and relevance of microbial EVs in human health.see on pubmed
Mitochondrial and Nuclear Mitochondrial Variants in Allergic Diseases.
Allergy Asthma Immunol Res. 2020 Sep , 12, (5):877-884.
The mitochondrial genome encodes core catalytic peptides that affect major metabolic processes within a cell. Here, we investigated the association between mitochondrial DNA (mtDNA) variants and allergic diseases, including atopic dermatitis (AD) and asthma, alongside heteroplasmy within the mtDNA in subjects with allergic sensitization. We collected genotype data from 973 subjects with allergic sensitization, consisting of 632 children with AD, 498 children with asthma, and 481 healthy (...)see on pubmed
Update on canine filaggrin: a review.
Vet Q. 2020 Dec , 40, (1):162-168.
Human filaggrin (FLG) plays a key role in epidermal barrier function, and loss-of-function mutations of its gene are primarily responsible for the development of human atopic dermatitis (AD). FLG expression is also reduced in the epidermis of atopic patients, due to the transcriptional effect of Th2 type cytokines. Canine atopic dermatitis (CAD) is a prevalent skin disease that shares many clinical and pathogenic features with its human homologue. The aim of this review is discuss current (...)see on pubmed